Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1310275 | 0.98 | TDP1 (0.58) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL13563913 | 0.85 | TSHR (0.56) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL9953900 | 0.84 | CYP2C9 (0.59) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| Hydrochloric Acid SCHEMBL7422764 | 0.82 | TDP1 (0.61) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL25226943 | 0.81 | CYP2C9 (0.39) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL27340963 | 0.81 | CYP2C9 (0.50) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL876467 | 0.81 | CYP2C9 (0.50) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL3929706 | 0.81 | TSHR (0.51) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL27803104 | 0.80 | CPB2 (0.51) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL3206853 | 0.80 | CYP2C9 (0.54) | CYP2C9TSHRCYP2C19MTORHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025064683-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-20 | — | — | US | disclosed |
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-4161902-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160075703-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-03-17 | — | — | US | disclosed |
| US-20150329543-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-11-19 | — | — | US | disclosed |
| US-20150259342-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150087652-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-03-26 | — | — | US | disclosed |
| US-20130289046-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2013-10-31 | — | — | US | disclosed |
| US-20110118279-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| US-20100093752-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| US-7662823-B2 | Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090306095-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-10 | — | — | US | disclosed |
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-7501420-B2 | Composition and antiviral of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-7354924-B2 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093752-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CYP2C9 1267/4885TSHR 4728/4885CYP2C19 804/4885 |
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IMPDH2, IDO1 | CYP2C9 905/4885TSHR 4407/4885CYP2C19 487/4885 |
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | CYP2C9 4402/4885TSHR 3881/4885CYP2C19 4392/4885 |
| US-20160075703-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | CYP2C9 1182/4885TSHR 4605/4885CYP2C19 592/4885 |
| US-20090306095-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | CYP2C9 2812/4885TSHR 4796/4885CYP2C19 1991/4885 |
| US-20130289046-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CYP2C9 1267/4885TSHR 4728/4885CYP2C19 804/4885 |
| US-20150087652-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CYP2C9 1267/4885TSHR 4728/4885CYP2C19 804/4885 |
| US-20150329543-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IMPDH2, IDO1 | CYP2C9 905/4885TSHR 4407/4885CYP2C19 487/4885 |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | CYP2C9 2812/4885TSHR 4796/4885CYP2C19 1991/4885 |
| US-20150259342-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | CYP2C9 1182/4885TSHR 4605/4885CYP2C19 592/4885 |
| US-20110118279-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CYP2C9 1267/4885TSHR 4728/4885CYP2C19 804/4885 |
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | CYP2C9 142/4885TSHR 4347/4885CYP2C19 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.